All In Biotech

Drug Trial Radar · NCT00203060

Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa

Last checked: Nov 20, 2026Latest source record: Apr 12, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 404 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

404

Actual

Start

Jul 1997

Primary completion

Jul 2000

Study completion Jul 2000

Sponsor

Lead sponsor
Teva Neuroscience, Inc.Teva (TEVA)
Sponsor type
Industry
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Who can join
All sexes, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.

Conditions

  • Parkinson's Disease

Interventions

  • Rasagiline MesylateDrug

    tablet, 1 or 2 mg, daily, 58 weeks

  • placeboDrug

    tablet, once daily, 58 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary objective is to assess the safety and efficacy of rasagiline in PD subjects, not receiving or requiring carbidopa/levodopa therapy. The primary efficacy measure will be the change in total UPDRS score, calculated from baseline to 26 weeks.Time frame: 58 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.